Literature DB >> 16595817

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.

C Andrew DeRyke1, Joseph L Kuti, Debra Mansfield, Adrian Dana, David P Nicolau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16595817     DOI： 10.2146/ajhp050323

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  3 in total

1.  Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.

Authors:  William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

Authors:  Jennifer Shiu; Erica Wang; Aaron M Tejani; Michael Wasdell
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

Review 3.  Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Authors:  Hui Yang; Chao Zhang; Quanyu Zhou; Yike Wang; Lujia Chen
Journal:  PLoS One       Date:  2015-01-09       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.